Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. (Nasdaq: CTKB) is a cell analysis solutions company focused on high-parameter flow cytometry using its patented Full Spectrum Profiling™ (FSP®) technology. This news page aggregates coverage of Cytek’s announcements so readers can follow developments related to its instruments, reagents, services and corporate activities.
Company press releases frequently address financial results and outlook, including quarterly revenue performance, recurring revenue trends from service and reagent businesses, and updates on installed instrument base. Cytek also issues news when it provides preliminary revenue expectations or reaffirms full-year guidance, and these items are often accompanied by Form 8-K filings summarizing results of operations.
Another major category of CTKB news involves product and technology updates. Recent communications have highlighted the launch of the Cytek Aurora™ Evo full spectrum flow cytometer, enhancements to small particle detection, and initiatives to expand access to advanced cytometry tools through instrument awards and research grants. The company also reports on the use of its FSP systems in peer-reviewed research and at scientific meetings.
Investors and researchers will also find corporate and recognition news, such as Cytek’s inclusion on TIME’s 2026 list of America’s Growth Leaders, expansion of its European headquarters in Amsterdam, and participation in healthcare and investor conferences hosted by organizations including UBS, Morgan Stanley, Stephens and Piper Sandler. Updates on collaborations with groups like the International Society for Advancement of Cytometry (ISAC) and presence at clinical cytometry conferences such as ESCCA and ICCS are also covered.
By reviewing CTKB news, users can track how Cytek communicates its financial performance, product evolution, geographic expansion and engagement with the scientific and investment communities over time.
Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced it will report its second quarter 2024 financial results after market close on Tuesday, August 6, 2024. The company's management will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results, business developments, and outlook. Investors can access the live audio webcast on the company's website at investors.cytekbio.com.
Cytek Biosciences announced a $50 million stock repurchase program, approved by its Board of Directors. This initiative aims to buy back shares of its common stock, listed under the Nasdaq symbol CTKB, up until December 31, 2024, unless modified. Repurchases will take place on the open market or through private transactions, adhering to SEC Rule 10b-18 and legal requirements. The program's extent and timing will depend on liquidity, cash flow, and market conditions. However, Cytek is not obliged to buy back any specific amount and may alter or suspend the program at any time.
Cytek Biosciences (Nasdaq: CTKB), a key player in cell analysis solutions, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL. Scheduled for June 12th at 9:20 a.m. Eastern Time, the company's management will engage in a fireside chat. The discussion will be accessible via a live and archived webcast on Cytek's investor relations webpage.
On May 28, 2024, Cytek Biosciences (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails received approval from China's National Medical Products Administration (NMPA) for clinical use. These reagents, used in the Cytek Northern Lights-Clinical (NL-CLC) cell analysis systems, aid in diagnosing and monitoring immune-related conditions such as immunodeficiencies, autoimmune diseases, infections, and cancers. The NMPA clearance marks the first clinical 1-laser based 6-color TBNK assay supported by Full Spectrum Profiling (FSP) capability. This approval enhances Cytek's market presence in China, offering new opportunities and strengthening its competitive edge. The Cytek NL-CLC systems are designed to perform optimally in multicolor environments, and their onboard volumetric meters reduce testing costs by eliminating the need for counting beads.
Cytek Biosciences has introduced the Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ and Cytek Northern Lights™ systems. This upgrade allows researchers to detect subcellular particles, such as extracellular vesicles (EVs), with superior sensitivity and resolution. The global EV market is projected to grow significantly, from $227.5 million in 2023 to $1.3 billion by 2028, at a CAGR of 42.2%. This advancement positions Cytek as a leader in the small particle research market. The ESP Detection Option enhances the study of viruses, bacteria, and nanoparticles, offering unprecedented light scatter sensitivity and enabling more accurate measurement and characterization of small particles.
Cytek Biosciences reported strong financial results for the first quarter of 2024, with total revenue reaching $44.9 million, a 21% increase from the previous year. The company's organic revenue saw a significant 11% growth, driven by the acquisition of product lines from Luminex Cytek also expanded its operations by opening a new facility in China and received approval for a TBNK panel. Despite a decrease in gross profit margin, the company remains focused on sustainable growth and profitability. Cytek reaffirmed its revenue guidance for 2024, expecting a positive net income for the year.
Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its Full Spectrum Profiling™ (FSP™) technology at CYTO 2024 and AAI’s IMMUNOLOGY2024. The company offers cell analysis solutions for various fields like immunology and oncology. They will conduct educational workshops, tutorials, and exhibit their suite of instruments, reagents, software, and services at these conferences.
Cytek Biosciences, Inc. (Nasdaq: CTKB) will report its first quarter 2024 financial results on May 8, 2024. The management will hold a conference call to discuss the results, business developments, and outlook.
Summary not available.
Summary not available.